Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer

BACKGROUND: In recent years, immunotherapy has achieved notable success in cancer treatment. Indeed, the novel immune checkpoint lymphocyte activation gene-3 (LAG3) has shown promising therapeutic efficacy in non-small cell lung cancer. However, it is unclear about the role of LAG3 in immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hui, Dai, Jiawei, Zhao, Lishu, Zhu, Jun, Wang, Hao, Chen, Peixin, Lu, Hui, Chen, Qiankun, Zhang, Zhemin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506769/
https://www.ncbi.nlm.nih.gov/pubmed/34734020
http://dx.doi.org/10.21037/atm-21-4481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506769/
https://www.ncbi.nlm.nih.gov/pubmed/34734020
http://dx.doi.org/10.21037/atm-21-4481

Ejemplares similares